Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Multiple risk factors for juvenile idiopathic arthritis (JIA) influence the microbiome, and various differences in the oral and fecal microbiome have been described to date in JIA. This review summarizes what is known and discusses potential implications for future research on the microbiome in JIA.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.rdc.2025.01.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Walking By Faith.
J Christ Nurs
September 2025
Christy Jeffcoat, DNP, RN, EBP-C, is an assistant professor at University of South Carolina College of Nursing. Her areas of interest include women's health, maternal mental health, juvenile idiopathic arthritis, lateral violence in nursing, and various aspects of evidence-based practice.
Serum biomarkers associated with baricitinib response in patients with juvenile idiopathic arthritis: a post-hoc analysis of the phase 3 JUVE-BASIS trial.
Lancet Rheumatol
September 2025
Bristol Royal Hospital for Children and Translational Health Sciences, Bristol, UK. Electronic address:
Background: Baricitinib has previously been shown to improve clinical response in patients with juvenile idiopathic arthritis (JIA) in the JUVE-BASIS trial. In this post-hoc analysis we aimed to identify whether pharmacodynamic changes in serum biomarkers in response to baricitinib treatment could help reaffirm the clinical utility of baricitinib in patients with JIA.
Methods: JUVE-BASIS was a randomised, double-blind, placebo-controlled, withdrawal, efficacy, safety, phase 3 trial, done in 75 centres in 20 countries.
Biomarkers for juvenile idiopathic arthritis treatment response-have we identified them?
Lancet Rheumatol
September 2025
Section of Rheumatology, Department of Pediatrics, Alberta Children's Hospital, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. Electronic address:
Tofacitinib as an adjuvant treatment for pediatric Still's disease.
Front Pediatr
August 2025
Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, China.
Objective: To describe the efficacy and safety of tofacitinib for pediatric Still's disease, also referred to as systemic-onset juvenile idiopathic arthritis (sJIA). Traditional non-biological drugs and drugs targeting the interleukin-1 and interleukin-6 pathways benefit some patients, but others show inadequate responses.
Methods: We retrospectively analyzed ten patients with pediatric Still's disease who were treated with tofacitinib and had at least one follow-up visit.
Vitamin D Status in Paraguayan Children With Autoimmune Diseases.
Int J Rheum Dis
September 2025
Department of Pediatrics, Facultad de Medicina, Universidad Nacional de Asunción, Asunción, Paraguay.
Introduction: Vitamin D plays a crucial role in modulating the immune system. Numerous studies have elucidated the association between low serum levels of vitamin D and autoimmune diseases. Vitamin D deficiency has been implicated in systemic lupus erythematosus, rheumatoid arthritis (RA), Hashimoto's thyroiditis, juvenile dermatomyositis, inflammatory bowel disease, among others.
View Article and Find Full Text PDF